Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Cash from Financing Activities: 2015-2024

Historic Cash from Financing Activities for Outlook Therapeutics (OTLK) over the last 10 years, with Sep 2024 value amounting to $60.3 million.

  • Outlook Therapeutics' Cash from Financing Activities rose 1059.78% to $660,771 in Q3 2020 from the same period last year, while for Sep 2020 it was $37.2 million, marking a year-over-year decrease of 4.65%. This contributed to the annual value of $60.3 million for FY2024, which is 23.20% up from last year.
  • Per Outlook Therapeutics' latest filing, its Cash from Financing Activities stood at $60.3 million for FY2024, which was up 23.20% from $49.0 million recorded in FY2023.
  • In the past 5 years, Outlook Therapeutics' Cash from Financing Activities ranged from a high of $60.3 million in FY2024 and a low of $37.2 million during FY2020.
  • Over the past 3 years, Outlook Therapeutics' median Cash from Financing Activities value was $59.6 million (recorded in 2022), while the average stood at $56.3 million.
  • As far as peak fluctuations go, Outlook Therapeutics' Cash from Financing Activities surged by 51.02% in 2021, and later decreased by 17.83% in 2023.
  • Outlook Therapeutics' Cash from Financing Activities (Yearly) stood at $37.2 million in 2020, then soared by 51.02% to $56.2 million in 2021, then rose by 6.05% to $59.6 million in 2022, then fell by 17.83% to $49.0 million in 2023, then grew by 23.20% to $60.3 million in 2024.